+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Astex Pharmaceuticals - logo

Astex Pharmaceuticals is a member of one of Japan's leading pharmaceutical companies, the Otsuka group. It focuses on developing small-molecule therapeutics with a focus on oncology and hematology. Its fragment-based drug discovery platform, Pyramid, has been successfully applied to therapeutic targets addressing a variety of disease areas. The company was formerly known as SuperGen Inc. and changed its name in September 2011. Astex was founded in 1991 and is headquartered in Dublin, California.

Cervical Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Cervical Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • October 2022
  • 700 Pages
  • Global
From
Next Generation Immune Checkpoint Inhibitors and Stimulators Market, 2020-2030 - Product Thumbnail Image

Next Generation Immune Checkpoint Inhibitors and Stimulators Market, 2020-2030

  • Report
  • February 2020
  • 360 Pages
  • Global
From
Myelodysplastic Syndrome - Pipeline Review, H1 2020 - Product Thumbnail Image

Myelodysplastic Syndrome - Pipeline Review, H1 2020

  • Drug Pipelines
  • June 2020
  • 1667 Pages
  • Global
From
Bladder Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Bladder Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • November 2022
  • 734 Pages
  • Global
From
Pheochromocytoma - Pipeline Insight, 2024 - Product Thumbnail Image

Pheochromocytoma - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 40 Pages
  • Global
From
Fallopian Tube Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Fallopian Tube Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • August 2022
  • 871 Pages
  • Global
From
Glioblastoma Multiforme (GBM) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Glioblastoma Multiforme (GBM) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • December 2022
  • 1036 Pages
  • Global
From
Small-Cell Lung Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Small-Cell Lung Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • November 2022
  • 574 Pages
  • Global
From
Non-Small Cell Lung Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Non-Small Cell Lung Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • December 2022
  • 2271 Pages
  • Global
From
Melanoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Melanoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • November 2022
  • 1699 Pages
  • Global
From
Non-Hodgkin Lymphoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Non-Hodgkin Lymphoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • October 2022
  • 1814 Pages
  • Global
From
Uveal Melanoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Uveal Melanoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • June 2022
  • 207 Pages
  • Global
From
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • December 2022
  • 1560 Pages
  • Global
From
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • October 2022
  • 232 Pages
  • Global
From
Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Global Market Report 2024 - Product Thumbnail Image

Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Global Market Report 2024

  • Report
  • February 2024
  • 175 Pages
  • Global
From
Peritoneal cancer - Pipeline Insight, 2024 - Product Thumbnail Image

Peritoneal cancer - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 220 Pages
  • Global
From
Head and Neck Cancer - Pipeline Insight, 2024 - Product Thumbnail Image

Head and Neck Cancer - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 230 Pages
  • Global
From
Mitogen Activated Protein Kinase 3 (ERT2 or Insulin Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or MAP Kinase Isoform p44 or Microtubule Associated Protein 2 Kinase or p44 ERK1 or MAPK3 or EC 2.7.11.24) - Pipeline Review, H2 201 - Product Thumbnail Image

Mitogen Activated Protein Kinase 3 (ERT2 or Insulin Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or MAP Kinase Isoform p44 or Microtubule Associated Protein 2 Kinase or p44 ERK1 or MAPK3 or EC 2.7.11.24) - Pipeline Review, H2 201

  • Drug Pipelines
  • August 2018
  • 56 Pages
  • Global
From
Acute Myeloid Leukemia (AML) Therapeutics - Global Strategic Business Report - Product Thumbnail Image

Acute Myeloid Leukemia (AML) Therapeutics - Global Strategic Business Report

  • Report
  • April 2024
  • 356 Pages
  • Global
From
Cancer CDK Inhibitor Global Market Insights 2023, Analysis and Forecast to 2028, by Market Participants, Regions, Technology, Application, Product Type - Product Thumbnail Image

Cancer CDK Inhibitor Global Market Insights 2023, Analysis and Forecast to 2028, by Market Participants, Regions, Technology, Application, Product Type

  • Report
  • October 2023
  • 140 Pages
  • Global
From
Loading Indicator